Conference Paper: A staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
| Title | A staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma |
|---|---|
| Authors | Chim, CS Lie, AKW Chan, EYT Leung, YY Cheung, SCW Chan, SYT Liang, R Kwong, YL |
| Issue Date | 2010 |
| Publisher | Fondazione Ferrata Storti. The Journal's web site is located at http://www.haematologica.org |
| Citation | The 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489 [How to Cite?] |
| Abstract | Bortezomib-based regimens have significant activities in multiple myeloma (MM). In this study, we tested the efficacy of a total therapy with a staged approach, where newly diagnosed MM patients received vincristine/adriamycin/dexamethsone (VAD). VAD-sensitive patients (375% paraprotein reduction) received autologous hematopoietic stem cell transplantation (auto-HSCT), whereas less VAD-sensitive patients (<75% paraprotein reduction) received bortezomib/thalidomide/dexamethasone (VTD) for further cytoreduction prior to auto-HSCT. On an intention-to treat analysis, a progressive increase of complete remission (CR) rates was observed, with cumulative CR rates of 48% after HSCT. Seven patients progressed leading to three fatalities, of which two had central nervous system disease. The 3-year overall-survival and event-free-survival (EFS) were 75.1% and 48.3%. Six patients developed oligoclonal reconstitution with new paraproteins. In the absence of anti-coagulant prophylaxis, no patients developed deep vein thrombosis. The staged application of VAD+/-VTD/auto-HSCT resulted in an appreciable response rate and promising survivals. Our approach reduced the use of bortezomib without compromising the ultimate CR rate, and is of financial significance for less affluent communities. |
| Description | Haematologica is supplement of the Hematology Journal This journal supplement is Abstract Book of 15th EHA 2010 |
| ISSN | 0390-6078 2011 Impact Factor: 6.424 2011 SCImago Journal Rankings: 0.681 |
| dc.contributor.author | Chim, CS |
|---|---|
| dc.contributor.author | Lie, AKW |
| dc.contributor.author | Chan, EYT |
| dc.contributor.author | Leung, YY |
| dc.contributor.author | Cheung, SCW |
| dc.contributor.author | Chan, SYT |
| dc.contributor.author | Liang, R |
| dc.contributor.author | Kwong, YL |
| dc.date.accessioned | 2010-10-31T12:27:23Z |
| dc.date.available | 2010-10-31T12:27:23Z |
| dc.date.issued | 2010 |
| dc.description.abstract | Bortezomib-based regimens have significant activities in multiple myeloma (MM). In this study, we tested the efficacy of a total therapy with a staged approach, where newly diagnosed MM patients received vincristine/adriamycin/dexamethsone (VAD). VAD-sensitive patients (375% paraprotein reduction) received autologous hematopoietic stem cell transplantation (auto-HSCT), whereas less VAD-sensitive patients (<75% paraprotein reduction) received bortezomib/thalidomide/dexamethasone (VTD) for further cytoreduction prior to auto-HSCT. On an intention-to treat analysis, a progressive increase of complete remission (CR) rates was observed, with cumulative CR rates of 48% after HSCT. Seven patients progressed leading to three fatalities, of which two had central nervous system disease. The 3-year overall-survival and event-free-survival (EFS) were 75.1% and 48.3%. Six patients developed oligoclonal reconstitution with new paraproteins. In the absence of anti-coagulant prophylaxis, no patients developed deep vein thrombosis. The staged application of VAD+/-VTD/auto-HSCT resulted in an appreciable response rate and promising survivals. Our approach reduced the use of bortezomib without compromising the ultimate CR rate, and is of financial significance for less affluent communities. |
| dc.description.nature | link_to_OA_fulltext |
| dc.description | Haematologica is supplement of the Hematology Journal |
| dc.description | This journal supplement is Abstract Book of 15th EHA 2010 |
| dc.description.other | The 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489 |
| dc.identifier.citation | The 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489 [How to Cite?] |
| dc.identifier.epage | 593 |
| dc.identifier.hkuros | 172211 |
| dc.identifier.issn | 0390-6078 2011 Impact Factor: 6.424 2011 SCImago Journal Rankings: 0.681 |
| dc.identifier.issue | s2 |
| dc.identifier.spage | 593 |
| dc.identifier.uri | http://hdl.handle.net/10722/126416 |
| dc.identifier.volume | 95 |
| dc.language | eng |
| dc.publisher | Fondazione Ferrata Storti. The Journal's web site is located at http://www.haematologica.org |
| dc.publisher.place | Italy |
| dc.relation.ispartof | Haematologica: the Hematology Journal |
| dc.title | A staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma |
| dc.type | Conference_Paper |